{"transactions":[{"id":1677527,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:01:40.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004525","document":"tm243270-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004525/tm243270-8_4seq1.xml","form_type":"4"}},{"id":1677526,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:01:40.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004525","document":"tm243270-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004525/tm243270-8_4seq1.xml","form_type":"4"}},{"id":2053513,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:04:50.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":197064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":197064,"derivative":{"exercise_price":0.0012,"exercise_date":"2024-01-17","expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":197064},"source":{"system":"sec-edgar","filing":"0001104659-23-004373","document":"tm231655-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923004373/tm231655-13_4seq1.xml","form_type":"4"}},{"id":2053512,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:04:50.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 17, 2025 and January 17, 2026, and 78,564 Ordinary Shares on January 17, 2027."}],"balance_after":314256,"derivative":{"exercise_price":0.0012,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-23-004373","document":"tm231655-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923004373/tm231655-13_4seq1.xml","form_type":"4"}},{"id":2053511,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:04:50.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.26 based on an exchange rate of U.S. $1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027."}],"balance_after":1407072,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-23-004373","document":"tm231655-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923004373/tm231655-13_4seq1.xml","form_type":"4"}},{"id":2435653,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-14T02:03:50.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 12, 2024 and January 12, 2025, and 78,564 Ordinary Shares on January 12, 2026."}],"balance_after":314256,"derivative":{"exercise_price":0.0014,"expiration_date":"2032-01-12","underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-22-004156","document":"tm221700-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922004156/tm221700-8_4seq1.xml","form_type":"4"}},{"id":2435652,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-14T02:03:50.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.44 based on an exchange rate of U.S. $1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026."}],"balance_after":1407072,"derivative":{"exercise_price":0.6,"expiration_date":"2032-01-12","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-22-004156","document":"tm221700-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922004156/tm221700-8_4seq1.xml","form_type":"4"}},{"id":2502209,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-11-19T13:22:11.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":498294.287,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"N/A"}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":498294.287},"source":{"system":"sec-edgar","filing":"0001104659-21-141738","document":"tm2133436-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141738/tm2133436-13_4seq1.xml","form_type":"4"}},{"id":2502208,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:22:11.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":12.03,"expiration_date":"2030-12-23","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-21-141738","document":"tm2133436-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141738/tm2133436-13_4seq1.xml","form_type":"4"}},{"id":2811276,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2021-03-04T02:01:21.000Z","date":"2021-03-03","kind":"exercise","acquired":true,"shares":1785000,"price":0.157,"value":280245.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 of $0.157 per ordinary share is derived from the option purchase price paid on March 3, 2021 of GBP0.112 per ordinary share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The 1,800,000 ordinary shares reported in Column 5 include 1,785,000 ordinary shares reported in Column 4 as well as 15,000 ordinary shares held by the Reporting Person. The ordinary shares reported in Column 5 represent solely the ordinary shares beneficially owned by the Reporting Person. Additionally, the Reporting Person holds options covering an aggregate of 9,703,672 ordinary shares of the Issuer. Ordinary shares may be represented by American Depositary Shares (ADSs) with each ADS representing six ordinary shares."}],"balance_after":1800000,"source":{"system":"sec-edgar","filing":"0001104659-21-031733","document":"tm218630-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465921031733/tm218630-1_4seq1.xml","form_type":"4"}},{"id":2910467,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-12T02:01:30.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":242712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on January 11, 2023 and January 11, 2024, and 60,678 Ordinary Shares on January 11, 2025."}],"balance_after":242712,"derivative":{"exercise_price":0.0014,"expiration_date":"2031-01-11","underlying":"Ordinary Shares","underlying_shares":242712},"source":{"system":"sec-edgar","filing":"0001104659-21-003131","document":"tm212800-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465921003131/tm212800-3_4seq1.xml","form_type":"4"}},{"id":2910466,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-12T02:01:30.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":1086816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.76 based on an exchange rate of U.S. $1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025."}],"balance_after":1086816,"derivative":{"exercise_price":1.03,"expiration_date":"2031-01-11","underlying":"Ordinary Shares","underlying_shares":1086816},"source":{"system":"sec-edgar","filing":"0001104659-21-003131","document":"tm212800-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465921003131/tm212800-3_4seq1.xml","form_type":"4"}},{"id":3068984,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"American Depositary Shares","published_at":"2020-08-05T01:02:23.000Z","date":"2020-08-03","kind":"sale","acquired":false,"shares":200000,"price":8.7409,"value":1748180.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019."},{"field":"shares","element":"transactionShares","label":"F3","text":"The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 15,000 ordinary shares and share options covering an aggregate of 10,159,144 ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $8.50 to $9.34, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-090469","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465920090469/a4.xml","form_type":"4"}},{"id":3307265,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-01-18T02:35:28.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":280896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S 1.302659 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023, and 70,224 Ordinary Shares on January 16, 2024."}],"balance_after":280896,"derivative":{"exercise_price":0.0013,"expiration_date":"2030-01-16","underlying":"Ordinary Shares","underlying_shares":280896},"source":{"system":"sec-edgar","filing":"0001104659-20-005262","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465920005262/a4.xml","form_type":"4"}},{"id":3307264,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-01-18T02:35:28.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":1257744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024."}],"balance_after":1257744,"derivative":{"exercise_price":0.74,"expiration_date":"2030-01-16","underlying":"Ordinary Shares","underlying_shares":1257744},"source":{"system":"sec-edgar","filing":"0001104659-20-005262","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465920005262/a4.xml","form_type":"4"}},{"id":3310543,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"American Depositary Shares","published_at":"2020-01-16T01:02:43.000Z","date":"2020-01-13","kind":"sale","acquired":false,"shares":50000,"price":5,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004422","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465920004422/a4.xml","form_type":"4"}},{"id":3310542,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"American Depositary Shares","published_at":"2020-01-16T01:02:43.000Z","date":"2020-01-13","kind":"sale","acquired":false,"shares":50000,"price":4,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004422","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465920004422/a4.xml","form_type":"4"}},{"id":3699819,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-09T02:01:52.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":224724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022, and 56,190 Ordinary Shares on January 4, 2023."}],"balance_after":224724,"derivative":{"exercise_price":0.0013,"expiration_date":"2029-01-04","underlying":"Ordinary Shares","underlying_shares":224724},"source":{"system":"sec-edgar","filing":"0001104659-19-001303","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465919001303/a4.xml","form_type":"4"}},{"id":3699818,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-09T02:01:52.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":1006224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 2, 2022 and 21,138 Ordinary Shares on January 4, 2023."}],"balance_after":1006224,"derivative":{"exercise_price":0.89,"expiration_date":"2029-01-04","underlying":"Ordinary Shares","underlying_shares":1006224},"source":{"system":"sec-edgar","filing":"0001104659-19-001303","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465919001303/a4.xml","form_type":"4"}},{"id":4097431,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T22:21:36.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":153648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 38,412 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 38,412 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022."}],"balance_after":153648,"derivative":{"exercise_price":0.0014,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":153648},"source":{"system":"sec-edgar","filing":"0001104659-18-002678","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465918002678/a4.xml","form_type":"4"}},{"id":4097430,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T22:21:36.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":687984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 171,996 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 14,333 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022."}],"balance_after":687984,"derivative":{"exercise_price":1.3,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":687984},"source":{"system":"sec-edgar","filing":"0001104659-18-002678","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465918002678/a4.xml","form_type":"4"}},{"id":4487844,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2017-01-18T22:01:00.000Z","date":"2017-01-13","kind":"grant","acquired":true,"shares":2072976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021."}],"balance_after":2072976,"derivative":{"exercise_price":0.72,"expiration_date":"2027-01-13","underlying":"Ordinary Shares","underlying_shares":2072976},"source":{"system":"sec-edgar","filing":"0001104659-17-002820","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465917002820/a4.xml","form_type":"4"}}]}